A loved one’s diagnosis moved this UCLA Health researcher to take on ALS

2022-04-06T14:40:49+00:00

A loved one’s diagnosis moved this UCLA Health researcher to take on ALS Computational geneticist developed a blood test that could detect how fast muscle cells are dying, potentially aiding diagnosis. After a parent is diagnosed with an incurable disease, it’s natural to feel an urge to do anything possible to help. For some people, that could be advocacy, or household assistance, or tracking down the best available medical care. For Noah Zaitlen, Phd, associate professor of computational medicine and neurology at UCLA Health, it meant launching a research project to create a better diagnostic test for a debilitating neurological [...]

A loved one’s diagnosis moved this UCLA Health researcher to take on ALS2022-04-06T14:40:49+00:00

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial

2021-09-07T16:20:38+00:00

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial Coya Therapeutics has raised $10 million in funding to advance the development of ALS001, a potential regulatory T-cell (Treg) therapy aiming to halt amyotrophic lateral sclerosis (ALS) progression, now in a Phase 2 study in patients. Proceeds raised in this series A funding round will also be used to introduce into testing similar treatments for other neurodegenerative disorders. “Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuro-protective effects of Treg cell therapy shows great potential in unlocking a new treatment paradigm [...]

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial2021-09-07T16:20:38+00:00

Answer ALS Launches ‘The Data is Here’ Campaign to Announce the Release of the World’s Largest Open Sourced ALS Data Portal

2021-09-07T16:20:38+00:00

Answer ALS Launches 'The Data is Here' Campaign to Announce the Release of the World's Largest Open Sourced ALS Data Portal The Answer ALS Data Portal seeks to empower researchers around the globe with the data needed to finally answer ALS NEW ORLEANS, Jan. 8, 2021 /PRNewswire/ -- Answer ALS, in cooperation with the Stephen Hawking Foundation, launches "The Data is Here" campaign on January 8 and on what would have been the famed Theoretical Physicist's 79th birthday. The campaign features a video tribute to Stephen Hawking and his tireless efforts to solve complex universal questions, while living with ALS for over 50 years. [...]

Answer ALS Launches ‘The Data is Here’ Campaign to Announce the Release of the World’s Largest Open Sourced ALS Data Portal2021-09-07T16:20:38+00:00

Multi-center, multi-tracer PET studies harmonized to detect neuroinflammation in ALS

2021-09-07T16:21:02+00:00

Multi-center, multi-tracer PET studies harmonized to detect neuroinflammation in ALS Reston, VA--A novel ALS (amyotrophic lateral sclerosis) study has pooled data from multiple sites to effectively visualize neuroinflammation, which is key to developing drugs to treat the disease. Pooling data acquired from different scanners, different neuroinflammation positron emission tomography (PET) markers and different sites enhanced researchers' ability to detect neuroinflammation in ALS patients. This research was published in the November issue of The Journal of Nuclear Medicine. ALS is a rare and fatal neurodegenerative disease that causes progressive weakness, respiratory failure and eventual death. Developing drugs to treat the disease [...]

Multi-center, multi-tracer PET studies harmonized to detect neuroinflammation in ALS2021-09-07T16:21:02+00:00

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

2021-09-07T16:21:02+00:00

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the first subject has been enrolled in the Phase 2a clinical trial evaluating AT-1501, the Company’s lead product candidate, in adults with amyotrophic lateral sclerosis (ALS). AT-1501 blocks the activation of the CD40L pathway, which has been shown to improve muscle function, slow [...]

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis2021-09-07T16:21:02+00:00

Aural Analytics To Power Speech-Based Endpoints For The Healey Center ALS Platform Trial at Mass General Hospital

2021-09-07T16:21:03+00:00

Aural Analytics To Power Speech-Based Endpoints For The Healey Center ALS Platform Trial at Mass General Hospital The first-ever platform trial for ALS is set to kick off this month and is led by investigators at the Sean M. Healey & AMG Center for ALS at Mass General Hospital Aural Analytics’ award-winning clinical trials platform will provide speech collection and speech-based digital endpoints for the HEALEY ALS Platform trial study regimens August 06, 2020 02:03 PM Eastern Daylight Time SCOTTSDALE, Ariz. & BOSTON--(BUSINESS WIRE)--Aural Analytics, Inc., a privately held digital health company developing the world’s most advanced suite of clinical-grade [...]

Aural Analytics To Power Speech-Based Endpoints For The Healey Center ALS Platform Trial at Mass General Hospital2021-09-07T16:21:03+00:00

ALS Drug Works in Study, Researchers Say

2021-09-07T16:21:24+00:00

An experimental drug slowed the paralyzing march of amyotrophic lateral sclerosis, or Lou Gehrig’s disease, in a clinical trial, according to researchers who say the results are a fresh sign that recent insights into the condition may soon bring new medicines.

ALS Drug Works in Study, Researchers Say2021-09-07T16:21:24+00:00

The ALS Association, ALS Finding A Cure, and MDA Co-Fund Clinical Trial Grant to Study Restoring Immune System Function to Treat ALS

2021-09-07T16:21:24+00:00

The ALS Association, ALS Finding A Cure, and MDA Co-Fund Clinical Trial Grant to Study Restoring Immune System Function to Treat ALS The ALS Association, ALS Finding a Cure (ALSFAC), and MDA announced they have jointly awarded a clinical trial grant totaling more than $2.5 million over two-and-a-half years to leading investigators at the Houston Methodist Neurological Institute and Massachusetts General Hospital. The principal investigator is Stanley Appel, MD, co-director of Houston Methodist Neurological Institute, chair of the Stanley H. Appel Department of Neurology and the Peggy and Gary Edwards Distinguished Chair in ALS at Houston Methodist Hospital, and professor [...]

The ALS Association, ALS Finding A Cure, and MDA Co-Fund Clinical Trial Grant to Study Restoring Immune System Function to Treat ALS2021-09-07T16:21:24+00:00

ALS Organizations Collaborate to Advance New Therapeutic into Trials

2021-09-07T16:21:45+00:00

ALS Organizations Collaborate to Advance New Therapeutic into Trials First dose of potential treatment AT-1501 given to humans by Anelixis Therapeutics to determine safety and tolerability Boston, MA (November 28, 2018) — Several ALS organizations announced on Wednesday that the first participant was successfully given a dose of AT-1501 in the first in-human trial of the potential treatment for ALS. AT-1501 was developed by the ALS Therapy Development Institute (ALS TDI), with support from The ALS Association, ALS ONE, and ALS Finding a Cure®, and is being brought into trials by Anelixis Therapeutics, Inc., a for-profit subsidiary of ALS TDI. The phase 1 [...]

ALS Organizations Collaborate to Advance New Therapeutic into Trials2021-09-07T16:21:45+00:00

The ALS Association and Prize4Life announce the ALS Assistive Technology Challenge

2021-09-07T16:21:45+00:00

The ALS Association and Prize4Life announce the ALS Assistive Technology Challenge After the tremendous success of the ALS Ice Bucket Challenge, ALS organizations are in a position to foster the creation of much needed solutions for people with ALS. One such solution is assistive technology for communication, which for people with ALS who struggle with communication or are completely unable to communicate, has the potential to be not just assistive but transformative. In April 2015, The ALS Association and Prize4Life organized a workshop for representatives of people with ALS and experts in the field of ALS technology to discuss how [...]

The ALS Association and Prize4Life announce the ALS Assistive Technology Challenge2021-09-07T16:21:45+00:00
Go to Top